This is a working overview of Melanotan II, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-01 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
In habitual users, however, tolerance develops rapidly; the perceived attention and alertness boost after overnight abstinence primarily reverses mild withdrawal deficits (fatigue, reduced concentration) rather than elevating performance above a true non-dependent baseline, consistent with the withdrawal-reversal hypothesis.
=== Generation === Progestins in birth control pills are sometimes grouped by generation. While the 19-nortestosterone progestins are consistently grouped into generations, the pregnane progestins that are or have been used in birth control pills are typically omitted from such classifications or are grouped simply as "miscellaneous" or "pregnanes". In any case, CPA has been described as a "first-generation" progestin similarly to closely related progestins like chlormadinone acetate, medroxyprogesterone acetate, and megestrol acetate.
The chief advantage sirolimus has over calcineurin inhibitors is its low toxicity toward kidneys. Transplant patients maintained on calcineurin inhibitors long-term tend to develop impaired kidney function or even kidney failure; this can be avoided by using sirolimus instead. It is particularly advantageous in patients with kidney transplants for hemolytic–uremic syndrome, as this disease is likely to recur in the transplanted kidney if a calcineurin-inhibitor is used. However, on 7 October 2008, the FDA approved safety labeling revisions for sirolimus to warn of the risk for decreased renal function associated with its use. In 2009, the FDA notified healthcare professionals that a clinical trial conducted by Wyeth showed an increased mortality in stable liver transplant patients after switching from a calcineurin inhibitor-based immunosuppressive regimen to sirolimus. A 2019 cohort study of nearly 10,000 lung transplant recipients in the US demonstrated significantly improved long-term survival using sirolimus + tacrolimus instead of mycophenolate mofetil + tacrolimus for immunosuppressive therapy starting at one year after transplant. Sirolimus can also be used either alone or in conjunction with a calcineurin inhibitor (such as tacrolimus) or mycophenolate mofetil, or both, to provide steroid-free immunosuppression regimens.
Sources: en.wikipedia.org
==== Hydrogen ==== The isotopic reference frame of Standard Mean Ocean Water (SMOW) was established by Harmon Craig in 1961 by measuring δ2H and δ18O in samples of deep ocean water previously studied by Epstein & Mayeda (1953). Originally SMOW was a purely theoretical isotope ratio intended to represent the mean state of the deep ocean. In the initial work the isotopic ratios of deep ocean water were measured relative to NBS-1, a standard derived from the steam condensate of Potomac River water. Notably, this means SMOW was originally defined relative to NBS-1, and there was no physical SMOW solution. Following the advice of an IAEA advisory group meeting in 1966, Ray Weiss and Harmon Craig made an actual solution with the isotopic values of SMOW which they called Vienna Standard Mean Ocean Water (VSMOW). They also prepared a second hydrogen isotope reference material from firn collected at the Amundsen-Scott South Pole Station, initially called SNOW and later called Standard Light Antarctic Precipitation (SLAP). Both VSMOW and SLAP were distributed beginning in 1968. The isotopic characteristics of SLAP and NBS-1 were later evaluated by interlaboratory comparison through measurements against VSMOW (Gonfiantini, 1978). Subsequently, VSMOW and SLAP were used as the primary isotopic reference materials for the hydrogen isotope system for multiple decades. In 2006 the IAEA Isotope Hydrology Laboratory constructed new isotopic reference materials called VSMOW2 and SLAP2 with nearly identical δ2H and δ18O as VSMOW and SLAP.
They may move along microfilament tracks, and the fact that the microfilament mesh changes shape to form a honeycomb structure surrounding the chloroplasts after they have moved suggests that microfilaments may help to anchor chloroplasts in place.
In economics, the term well-being is used for one or more quantitative measures intended to assess the quality of life of a group, for example, in the capabilities approach and the economics of happiness. As with the related cognate terms 'wealth' and 'welfare', economics sources often contrast the state with its opposite. The study of well-being is divided into subjective well-being and objective well-being.
Sources: en.wikipedia.org
The election of Abraham Lincoln in 1860 drastically intensified the secession debate in Knoxville, and the city's leaders met on November 26 to discuss the issue. Those who favored secession, such as J.G.M. Ramsey, believed it was the only way to ensure the rights of Southerners. Those who rejected secession, such as Maynard and Temple, believed that East Tennesseans, most of whom were yeoman farmers, would be rendered subservient to a government dominated by Southern planters. In February 1861, Tennessee held a vote on whether or not to hold a statewide convention to consider seceding and joining the Confederacy. In Knoxville, 77% voted against this measure, affirming the city's allegiance to the Union. Throughout the first half of 1861, Brownlow and J. Austin Sperry (the radical secessionist editor of the Knoxville Register) assailed one another mercilessly in their respective papers, and Union and Secessionist leaders blasted one another in speeches across the region. Simultaneous Union and Confederate recruiting rallies were held on Gay Street. Following the attack on Fort Sumter in April, Governor Isham Harris made moves to align the state with the Confederacy, prompting the region's Unionists to form the East Tennessee Convention, which met at Knoxville on May 30, 1861. The convention submitted a petition to Governor Isham Harris, calling his actions undemocratic and unconstitutional.
Basic diagnostic medical devices (e.g., stethoscope, tongue depressor) are typically used. After examining for signs and interviewing for symptoms, the doctor may order medical tests (e.g., blood tests), take a biopsy, or prescribe pharmaceutical drugs or other therapies. Differential diagnosis methods help to rule out conditions based on the information provided. During the encounter, properly informing the patient of all relevant facts is an important part of the relationship and the development of trust within the context of the doctor-patient relationship. The medical encounter is then documented in the medical record, which is a legal document in many jurisdictions. Follow-up encounters may be shorter but follow the same general procedure, and specialists follow a similar process. The diagnosis and treatment may take only a few minutes or a few weeks, depending on the complexity of the issue. The components of the medical interview and encounter are:
== D == DE(T)A – Dielectric thermal analysis dHvA – De Haas–van Alphen effect DIC – Differential interference contrast microscopy Dielectric spectroscopy DLS – Dynamic light scattering DLTS – Deep-level transient spectroscopy DMA – Dynamic mechanical analysis DPI – Dual polarisation interferometry DRS – Diffuse reflection spectroscopy DSC – Differential scanning calorimetry DTA – Differential thermal analysis DVS – Dynamic vapour sorption
The two substrates of this enzyme are D-mannonic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are D-mannuronic acid (shown in open-chain form), reduced NADH, and a proton. The enzyme can also use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-mannonate:NAD(P)+ 6-oxidoreductase. Other names in common use include mannonate dehydrogenase, mannonate (nicotinamide adenine dinucleotide, (phosphate))dehydrogenase, mannonate dehydrogenase, mannuronate reductase, mannonate dehydrogenase (NAD(P)+), D-mannonate:nicotinamide adenine dinucleotide (phosphate, and oxidoreductase (D-mannuronate-forming)).
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.